1169 related articles for article (PubMed ID: 25775313)
1. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
6. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
Elsisi GH; Aburawash A; Waked E
Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
Liu S; Watcha D; Holodniy M; Goldhaber-Fiebert JD
Ann Intern Med; 2014 Oct; 161(8):546-53. PubMed ID: 25329202
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Linas BP; Barter DM; Morgan JR; Pho MT; Leff JA; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Freedberg KA; Kim AY
Ann Intern Med; 2015 May; 162(9):619-29. PubMed ID: 25820703
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
14. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection.
Zhou H; Lu Y; Wu B; Che D
Pediatr Infect Dis J; 2020 Jun; 39(6):e59-e65. PubMed ID: 32345829
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Ward T; Webster S; Mishina S; McEwan P; Wygant G; Wang F
Value Health Reg Issues; 2017 May; 12():1-6. PubMed ID: 28648305
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
[TBL] [Abstract][Full Text] [Related]
19. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]